• Our Company
  • Our Science
  • Our Pipeline
  • Join Us
  • Investors & Media
    • News & Events
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources
Kodiak Sciences
  • Our Company
  • Our Science
  • Our Pipeline
  • Join Us
  • Investors & Media
    • News & Events
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources

Pushing the boundaries

At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness

ABC PlatformTM

Our biologics-based medicines are built on a proprietary high science Antibody Biopolymer Conjugate or ABC Platform designed to maintain potent and effective drug levels in key ocular tissues for longer than currently available therapies.

+

Protein Sciences

  • Novel monospecific and bispecific antibody proteins
  • Identical antibody frameworks with reduced immune effector functions
  • Engineered for site-specific biopolymer conjugation

=

Biopolymer Engineering

  • Phosphorylcholine-based biopolymer
  • Branched ultra-high molecular weights
  • Optically clear aqueous solutions

ABC MedicinesTM

  • Large size translates to superior ocular durability
  • High water content allows high bioavailability in key ocular target tissues
  • High affinity and potency (picomolar)
  • High formulation strength

Optimizing size and dose for maximum durability

Size

In general, the larger the size, the longer the molecule will remain in the eye.

Drug per dose

Drug per dose is how many target binding units fit into the injected clinical dose.

Ocular half-life

Ocular half-life is how long the drug lasts in the eye which is a key driver of durability.

Take a 3-Dimensional Tour

Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360o below.

Click and drag to see different views. Scroll or pinch to zoom.

Kodiak Bioconjugate
by kodiaksciencesinc
on Sketchfab

Please be patient while the 3-D model loads

CLiP PlatformTM
The power of 500 small molecules in one

Our chemistry-based medicines are built on our proprietary Controlled ‘Living’ Polymerization of phosphorylcholine-containing and drug-containing co-monomers, our CLiP PlatformTM, which is designed to achieve high biocompatibility with high drug loading and sustained release of bioactives for ophthalmology.

+

Small Molecule Chemistry

  • Broadly applicable across a range of drug formats such as traditional small molecules, macrocyclics, nucleic acids and peptidomimetics
  • Linker technologies for sustained release of unmodified drugs

=

Biopolymer Engineering

  • Phosphorylcholine-based biopolymer drives extreme biocompatibility
  • Branched ultra-high molecular weights
  • Tight control of monomer-to-comonomer ratio via controlled ‘living’ polymerization

CLiP MedicinesTM

  • Large size translates into best in class ocular durability
  • High drug loading of > 500 per bioconjugate
  • Tailored release of unmodified drugs
  • High aqueous solubility

Contact

Name:

Email:

Subject:

Message:

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

Kodiak Sciences

2631 Hanover Street
Palo Alto, CA 94304

Copyright © 2019 Kodiak Sciences Inc.